- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Cellectis SA(CLLS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CLLS
11/13/2026: CLLS (1-star) is currently NOT-A-BUY. Pass it for now.
Cellectis SA is a clinical-stage biotechnology company that develops allogeneic cell therapies and in vivo gene editing treatments. The company's main strengths lie in its proprietary TALEN gene-editing technology and internal manufacturing capabilities. Its primary growth story centers on advancing off-the-shelf CAR-T candidates and expanding into in vivo genomic medicines for chronic diseases. Key risks include ongoing cash burn, high market competition, and clinical trial execution hurdles. The stock is best suited for growth-oriented investors willing to tolerate high volatility, with key developments centered on upcoming clinical trial data readouts and partnership updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Cellectis offers exposure to high-growth genetic medicine and gene-editing market trends. |
| Momentum investor | Mixed fit | Momentum depends heavily on episodic clinical trial data readouts and partnership announcements. |
| Value investor | Weak fit | The company is a pre-profit, clinical-stage biotech with ongoing operating losses. |
| Dividend investor | Weak fit | Cellectis pays no dividends and retains all capital for clinical development. |
| Low-risk investor | Weak fit | High clinical development risks and share price volatility make it unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks frequently experience sharp price swings based on trial updates. |
| Valuation risk | Medium / high | Valuations are heavily tied to speculative future clinical successes rather than current earnings. |
| Competition risk (gene editing & cell therapy) | High | Rapid technological advancements by rival genomic medicine companies threaten market positioning. |
| Business quality | Medium | The company possesses strong proprietary science and technology platforms, but lacks commercial commercialized product sales. |
| Dividend income | Low / none | No dividend is paid or expected in the near term. |
| Execution risk | High | Success relies entirely on navigating complex clinical trials, manufacturing scaling, and regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 118.86M USD | Price to earnings Ratio - | 1Y Target Price 4.45 |
Price to earnings Ratio - | 1Y Target Price 4.45 | ||
Volume (30-day avg) 95.4K shares | Beta 2.94 | 52 Weeks Range 0.88 - 5.45 | Updated Date 11/15/2026 |
52 Weeks Range 0.88 - 5.45 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -29.76% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research Collaborations and Licensing | Upfront licensing fees, research funding, and milestone payments from biopharmaceutical partners utilizing Cellectis's technology. | Revenue can be lumpy and depends heavily on partner activity and successful development milestones. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-12 | When After Market | Estimate -0.21 | Actual 0.01 |
Profitability
Profit Margin - | Operating Margin (TTM) -384.93% |
Management Effectiveness
Return on Assets (TTM) -27.75% | Return on Equity (TTM) -307.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35.26M | Price to Sales(TTM) 3.7 |
Enterprise Value 35.26M | Price to Sales(TTM) 3.7 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA -3.9 | Shares Outstanding 72.73M | Shares Floating 67.30M |
Shares Outstanding 72.73M | Shares Floating 67.30M | ||
Percent Insiders 0.07 | Percent Institutions 13.44 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

